Orme ME, et al. – A Bayesian network meta–analysis (NMA) of placebo– and active–controlled randomized trials was conducted to evaluate the comparative effectiveness of liraglutide, albiglutide, dulaglutide, and exenatide twice daily and once weekly, with a focus on glycemic control. It was concluded that GLP–1 receptor agonists (GLP–1 RAs) are a viable addition to oral antidiabetes therapy, and dulaglutide, exenatide once weekly, and liraglutide are the most effective.